Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database
Abstract: The U.S. Food and Drug Administration (FDA) has stated that the prescription of remdesivir should be cautious for patients with estimated glomerular filtration rate (eGFR) < 30 and some studies reported risk of adverse renal events. The available information on the renal safety profile...
Shranjeno v:
Main Authors: | , , , |
---|---|
Format: | Knjiga |
Izdano: |
Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz,
2021-11-01T00:00:00Z.
|
Teme: | |
Online dostop: | Connect to this object online. |
Oznake: |
Označite
Brez oznak, prvi označite!
|
Internet
Connect to this object online.3rd Floor Main Library
Signatura: |
A1234.567 |
---|---|
Kopija 1 | Prosto |